Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orland, J. R.
Right arrow Articles by Murphy, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orland, J. R.
Right arrow Articles by Murphy, E. L.
Related Collections
Right arrow All Infections
Right arrow Viral infections
Right arrow Spastic paraplegia
NEUROLOGY 2003;61:1588-1594
© 2003 American Academy of Neurology

Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study

J. R. Orland, MD, J. Engstrom, MD, J. Fridey, MD, R. A. Sacher, MD, J. W. Smith, MD, C. Nass, PhD, G. Garratty, PhD, B. Newman, MD, D. Smith, B. Wang, MD DrPH, K. Loughlin and E. L. Murphy, MD MPH for the HTLV Outcomes Study (HOST)*

From the University of California San Francisco (Drs. Orland, Engstrom, and Murphy); Blood Centers of the Pacific (Drs. Orland and Murphy), San Francisco; City of Hope National Medical Center (Dr. Fridey), Duarte, CA; Hoxworth Blood Center and University of Cincinnati (Dr. Sacher), OH; Oklahoma Blood Institute (Dr. J.W. Smith), Oklahoma City; American Red Cross Blood Services, Chesapeake Region (Dr. Nass), Baltimore, MD; American Red Cross Blood Services, Southern California Region (Dr. Garratty), Los Angeles; American Red Cross Blood Services, Southeastern Michigan Region (Dr. Newman), Detroit; and Westat (D. Smith, Dr. Wang, and K. Loughlin), Rockville, MD.

Address correspondence and reprint requests to Dr. Jennie R. Orland, UCSF Department of Epidemiology and Biostatistics and Blood Centers of the Pacific, 270 Masonic Ave., San Francisco, CA 94118; e-mail: orland{at}itsa.ucsf.edu

Background: Almost 20 years after its discovery, the prevalence and clinical course of human T-lymphotropic virus type I (HTLV-I)–associated myelopathy (HAM, also known as tropical spastic paraparesis [TSP]) remain poorly defined. Whereas the causative association of HTLV-I and HAM/TSP is generally recognized, controversy still surrounds the relationship between HTLV-II and HAM/TSP.

Methods: The HTLV Outcomes Study (HOST—formerly Retrovirus Epidemiology Donor Study [REDS]) is a prospective cohort study including 160 patients with HTLV-I, 405 patients with HTLV-II, and 799 uninfected controls who have been followed every 2 years since 1990–1992. Clinical outcomes are measured by health interviews and examinations, and blood samples are obtained.

Results: Six cases of HTLV-I–associated myelopathy (3.7%, 95% CI 1.4 to 8.0) and four cases of HTLV-II myelopathy (1.0%, 95% CI 0.3 to 2.5) have been diagnosed since the formation of the cohort. There have been no cases of HAM/TSP diagnosed among HTLV-negative subjects (0.0%, 95% CI 0.0 to 0.5). Clinical features of the cases include lower extremity hyperreflexia, variably associated with weakness, spasticity, and bladder dysfunction.

Conclusions: Systematic screening of HTLV-infected blood donors reveals a high prevalence of HAM/TSP. The clinical course of HAM/TSP appears highly variable. HTLV-II–associated myelopathy generally presents with milder and more slowly progressive signs and symptoms.

Received March 14, 2003. Accepted in final form August 4, 2003.

*A list of all HOST investigators is given in the Appendix on page 1593.




This article has been cited by other articles:


Home page
 NeurologyHome page
H. H. Biswas, J. W. Engstrom, Z. Kaidarova, G. Garratty, J. W. Gibble, B. H. Newman, J. W. Smith, A. Ziman, J. L. Fridey, R. A. Sacher, et al.
Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy
Neurology, September 8, 2009; 73(10): 781 - 789.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Cooper, M Schim van der Loeff, S McConkey, M Cooper, R Sarge-Njie, S Kaye, and H Whittle
Neurological morbidity among human T-lymphotropic-virus-type-1-infected individuals in a rural West African population
J. Neurol. Neurosurg. Psychiatry, January 1, 2009; 80(1): 66 - 68.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
S H Wong, M Boggild, T P Enevoldson, and N A Fletcher
Myelopathy but normal MRI: where next?
Practical Neurology, April 1, 2008; 8(2): 90 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
P. Martin-Davila, J. Fortun, R. Lopez-Velez, F. Norman, M. Montes de Oca, P. Zamarron, M. I. Gonzalez, A. Moreno, T. Pumarola, G. Garrido, et al.
Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation
Clin. Microbiol. Rev., January 1, 2008; 21(1): 60 - 96.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Meertens, S. Chevalier, R. Weil, A. Gessain, and R. Mahieux
A 10-Amino Acid Domain within Human T-cell Leukemia Virus Type 1 and Type 2 Tax Protein Sequences Is Responsible for Their Divergent Subcellular Distribution
J. Biol. Chem., October 8, 2004; 279(41): 43307 - 43320.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.